SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SABS

SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · USD
Healthcare · Biotechnology
$2.81-$0.10 (-3.44%)
 
Market cap
$253M
Insider Score
Analyst consensus
Website
Market Cap$253.15M-26.1%
Revenue (ttm)n/a
Net Income-$66.50M
EPS-$1.35
Shares Out90.09M
PE Ration/a
Forward PE-2.98
Dividendn/a
Ex-Dividend Daten/a
Volume874,566
Open$2.79
Previous Close$2.91
Day's Range$2.63 - $2.88
52-Week Range$2.44 - $5.15
Beta0.75
AnalystsStrong Buy
Price Target$11.64(+314.11%)
Earnings DateNov 5, 2026

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Address
777 W 41st St., Miami Beach, FL, 33140, United States
Market Cap
253 million
Employees
86
Industrial Classification
Biotechnology
1 Day
-3.44%
5 Days
-5.07%
1 Month
-7.57%
6 Months
-27.95%
1 Year
-26.05%

$SABS stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SABS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SABS's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SABS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New SABS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SABS from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from SABS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: FDA Fast-Track designation and pivotal diabetes trial data drive bullish analyst commentary; Q3 results and earnings call support constructive outlook.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SURISimplify Propel Opportunities ETF0.42%
SBIOALPS Medical Breakthroughs ETF0.18%

Weight is the stock’s share of each fund’s holdings.